Clinical Trial Update: A Study of People With CD30 Positive Lymphoma in China

View source ↗

Summary

Takeda-sponsored clinical trial in China evaluating CD30-positive lymphoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma

Snippet

Sponsor: Takeda | Conditions: Lymphoma | Status: COMPLETED